RxSight, Inc.
RXST
$13.99
$0.685.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 148.31M | 139.93M | 128.29M | 115.18M | 101.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 148.31M | 139.93M | 128.29M | 115.18M | 101.10M |
| Cost of Revenue | 41.72M | 40.98M | 40.48M | 38.86M | 37.02M |
| Gross Profit | 106.59M | 98.94M | 87.81M | 76.32M | 64.09M |
| SG&A Expenses | 106.80M | 101.49M | 94.46M | 87.99M | 81.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.17M | 176.78M | 167.37M | 157.55M | 148.76M |
| Operating Income | -36.86M | -36.86M | -39.08M | -42.37M | -47.66M |
| Income Before Tax | -26.49M | -27.41M | -30.67M | -36.75M | -44.47M |
| Income Tax Expenses | 59.00K | 50.00K | 20.00K | 19.00K | 29.00K |
| Earnings from Continuing Operations | -26.55 | -27.46 | -30.69 | -36.77 | -44.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.55M | -27.46M | -30.69M | -36.77M | -44.50M |
| EBIT | -36.86M | -36.86M | -39.08M | -42.37M | -47.66M |
| EBITDA | -33.63M | -33.28M | -34.97M | -38.31M | -43.42M |
| EPS Basic | -0.67 | -0.71 | -0.82 | -1.01 | -1.25 |
| Normalized Basic EPS | -0.42 | -0.44 | -0.51 | -0.61 | -0.75 |
| EPS Diluted | -0.67 | -0.71 | -0.82 | -1.01 | -1.25 |
| Normalized Diluted EPS | -0.42 | -0.44 | -0.51 | -0.61 | -0.75 |
| Average Basic Shares Outstanding | 159.11M | 155.44M | 151.05M | 146.92M | 142.97M |
| Average Diluted Shares Outstanding | 159.11M | 155.44M | 151.05M | 146.92M | 142.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |